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Still, there is need for significant improvements in reliable and accurate diagnosis for
Alzheimer’s disease (AD) at early stages. It is widely accepted that changes in the
concentration and conformation of amyloid-β (Aβ) appear several years before the onset
of first symptoms of cognitive impairment in AD patients. Because Aβ oligomers are
possibly the major toxic species in AD, they are a promising biomarker candidate for the
early diagnosis of the disease. To date, a variety of oligomer-specific assays have been
developed, many of them ELISAs. Here, we demonstrate the sFIDA assay, a technology
highly specific for Aβ oligomers developed toward single particle sensitivity. By spiking
stabilized Aβ oligomers to buffer and to body fluids from control donors, we show that the
sFIDA readout correlates with the applied concentration of stabilized oligomers diluted
in buffer, cerebrospinal fluid (CSF), and blood plasma over several orders of magnitude.
The lower limit of detection was calculated to be 22 fM of stabilized oligomers diluted in
PBS, 18 fM in CSF, and 14 fM in blood plasma.
Keywords: Alzheimer’s disease, amyloid-β peptide, diagnostic biomarker, early diagnosis, sFIDA, surface-based
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INTRODUCTION
Worldwide 5–7% of people older than 60 years are affected by dementia, with Alzheimer’s disease
(AD) being the most common type. Due to the aging population, the total number of demented
people is predicted to increase even further (Prince et al., 2013). There is neither a cure nor
a sufficiently reliable laboratory diagnostic test available for this fatal neurodegenerative disease
(Lansdall, 2014). Early diagnosis of AD, however, is of great importance for the development of
therapeutics and their future application at an early stage of the disease. It is believed that AD
can be treated most effectively in preclinical stages, before cognitive functions become impaired
and neurons and synapses are damaged irreversibly (Golde et al., 2011). Hitherto, the definitive
diagnosis can only be made after the patients’ death based on neuropathological hallmarks, like
amyloid plaques, neurodegeneration and neurofibrillary tangles (Ballard et al., 2011).
The main component of amyloid plaques is amyloid β peptide (Aβ), which is formed from the
amyloid precursor protein (APP) by β- and γ-secretases (Haass et al., 2012). Once released from
the precursor, the Aβ peptide is prone to aggregation and can assemble into oligomeric structures
and amyloid fibrils. It is widely accepted that soluble Aβ oligomers but not monomers are highly
neurotoxic and that the pathological process in AD starts already years before the onset of clinical
manifestation (Braak and Braak, 1991; McLean et al., 1999; Cleary et al., 2004; Lesné et al., 2006).
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Currently, the total concentration of Aβ42 in cerebrospinal fluid
(CSF), which is lower in AD patients compared to healthy
persons (Sunderland et al., 2003; Shaw et al., 2009), is used as
a biomarker in clinical trials or academic settings to increase
the accuracy of AD diagnosis. At the current stage of biomarker
development, however, the total concentration of Aβ42 in CSF,
even in combination with other biomarkers such as tau protein,
does not allow a clear distinction of AD patients from healthy
controls or patients with other dementias (Humpel, 2011).
Therefore, the development of more accurate biomarkers is of
utmost importance.
Since Aβ oligomeric species are known to be directly involved
in AD pathology or even to trigger the disease (Haass and Selkoe,
2007), Aβ oligomers are considered as promising biomarker for
AD (Blennow et al., 2010). The main challenges for Aβ oligomer-
based diagnostics in body fluids are the presumably very low
concentrations of Aβ oligomers and the high background of
monomeric Aβ (Rosén et al., 2013). To meet those requirements,
we have previously developed an assay called sFIDA (surface-
based fluorescence intensity distribution analysis; Birkmann
et al., 2007; Funke et al., 2007, 2010; Bannach et al., 2012). The
principle of sFIDA is illustrated in Figure 1. The biochemical
setup of sFIDA resembles a conventional sandwich ELISA. All Aβ
species are immobilized on a functionalized glass surface via Aβ-
specific capture antibodies. After immobilization, Aβ aggregates
are multiply loaded by at least two detection antibodies, each
of them labeled with a different fluorochrome. Because capture
and detection antibodies recognize the same or an overlapping
epitope on Aβ, Aβ monomers cannot bind any detection
antibodies while bound to the capture antibody. In contrast to
a classical ELISA, the result of the measurement is not a single
readout for the whole sample. Instead, the surface is imaged by
high-resolution fluorescencemicroscopy, such as dual-color total
internal reflection fluorescence microscopy (TIRFM). Only those
FIGURE 1 | Scheme of the sFIDA assay. Aβ-specific capture antibodies
(dark gray Y symbols) are immobilized on a functionalized glass surface. Aβ
oligomers (brown rods) present in the sample bind to the capture antibodies
and are detected by fluorescence labeled (colored stars) anti-Aβ-antibodies
(light gray Y symbols). The surface is then imaged by dual-color microscopy. In
this version of the assay, all three of the applied antibodies (one capture and
two different detection antibodies labeled with two different fluorochromes)
bind to overlapping epitopes at the N-terminus of Aβ, which corresponds to
the spiky ends of the brown rods in the scheme above. Thereby, only
oligomers with multiple epitopes, but not monomers, are able to bind detection
antibodies while bound to the capture and thus yield detectable signals.
pixels that show signal intensities above the background noise
in both channels are counted. Thus, the number of colocalized
pixels above the background noise is expected to correlate with
the concentration of Aβ oligomers in the sample.
Results showing increased sFIDA readouts for AD patients
compared to non-demented controls have been reported
previously (Wang-Dietrich et al., 2013). However, in this study no
reliable Aβ oligomer standard was available to determine absolute
concentrations from the assay readout. Due to both the dynamic
aggregation and dissociation of Aβ, non-stabilized oligomers are
not suited as standard in oligomer-based diagnostic assays.
Here, we demonstrate application of stabilized Aβ oligomers
as standard molecules in the sFIDA assay. The sFIDA readout
correlates with the applied oligomer concentration over five
magnitudes down to a femtomolar range, which will allow the
quantification of natural Aβ oligomer concentrations in body
fluids.
MATERIALS AND METHODS
Biological Samples and PBS Spiked with
Stabilized Oligomers
Four individual human EDTA-anticoagulated plasma samples
(Zen-Bio, Research Triangle Park, USA) and one pooled human
EDTA-anticoagulated plasma sample from three healthy donors
were centrifuged for 15min at 15,000 × g. The supernatant was
collected and equal volumes from each sample were combined to
obtain one large pool from several donors (from here on referred
to as “plasma fraction”). Human cerebrospinal fluid sample
(CSF; pooled from healthy donors/mixed gender) was purchased
from Biochemed (Winchester, USA). Stabilized Aβ oligomers
(Crossbeta Biosciences B.V., Utrecht, the Netherlands), from
here on called “oligomers”, were serially diluted from the stock
solution (10 nM) to concentrations of 1 nM, 100 pM, 10 pM,
1 pM, 100 fM, 10 fM, and 1 fM in PBS (GE Healthcare, Chalfont
St. Giles, UK), CSF or the plasma fraction as described above.
All concentrations of Aβ oligomers in this publication refer
to oligomer particle concentrations, if not stated otherwise.
The oligomers consist of approximately 220 Aβ1–42 monomers
(manufacturer’s data); further characterization of the stabilized
oligomers, including data on the size homogeneity and stability,
are available on the manufacturer’s homepage (Crossbeta
Biosciences, 2015).
sFIDA
Plate Preparation
384-well plates (SensoPlate Plus with 175µm glass bottom;
Greiner Bio-One, Kremsmünster, Austria) were used for sFIDA.
Functionalization of the glass surface was performed as
previously described in Janissen et al. (2009). The surface was
treated with 5M NaOH (AppliChem, Darmstadt, Germany)
for 15min, washed three times with water, neutralized with
1M HCl (AppliChem, Darmstadt, Germany; 15min), washed
again three times with water and then twice with 70% ethanol
(VWR International, Langenfeld, Germany). After drying the
plate at room temperature, the wells were incubated in
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10M ethanolamine in DMSO (Sigma-Aldrich, St. Louis, USA)
overnight. Afterwards, the wells were washed three times with
DMSO, twice with 70% ethanol and the plate was dried again
at room temperature. A solution of 50mM SC-PEG-CM (MW
5000 Da, Laysan Bio, Arab, USA) in DMSO was heated shortly to
70◦C until the PEG dissolved. After the solution cooled down, 2%
(v/v) triethylamin (Fluka, Buchs, Switzerland) were added, the
solution was quickly vortexed and 15µl were applied per well.
After an incubation time of 1 h the wells were washed five times
with water.
The carboxymethyl groups of SC-PEG-CM on the glass
surface were then activated by addition of 30µl of 100mM EDC
(Fluka, Buchs, Switzerland)/100mM NHS (Aldrich, Milwaukee,
USA) in 0.1M MES buffer, pH 3.5 (AppliChem) per well for
30min. After flushing the wells three times quickly with MES
buffer, 15µl of 10 ng/µl capture antibody Nab228 in PBS (the
supernatant after centrifuging 10min at 18,000 g) was added to
the surface. After incubating for 90min, unbound antibody was
removed and wells were washed three times with PBST (PBS
+ 0.05% Tween20, AppliChem Panreac, Darmstadt, Germany)
and three times with PBS. Then 50µl of blocking solution
(SmartBlock, CANDOR Biosciences, Wangen, Germany) per
well were incubated for 1 h. After washing the wells three times
with PBST and three times with PBS, 15µl sample was applied to
each well and incubated overnight. The wells were washed once
with PBST and twice with PBS. The detection antibodies 6E10
labeled with Alexa Fluor 488 (Covance, Princeton, USA) and
Nab228 labeled with Alexa Fluor 647 (Santa Cruz, Dallas, USA)
were combined to each 1.25µg/ml in PBS and centrifuged for 1 h
(100,000 g, 4◦C). The supernatant was mixed and added to the
wells (15µl/well, 1 h). Finally, the wells were washed once with
PBST and twice with PBS. The buffer was removed and 100µl of
water were applied to each well for image acquisition on TIRFM
(AM TIRF MC, Leica microsystems, Wetzlar, Germany).
Image Data Acquisition
Using TIRF microscopy, 25 positions per well were imaged in
two different channels (14 bit gray scale; channel 0: excitation
at 635 nm, emission filter 705/72 nm; channel 1: excitation at
488 nm, emission filter 525/36 nm). Each image contains 1000 ×
1000 pixels and represents an area of 116 × 116µm. In total,
3.15% of the well surface was imaged.
Image Data Analysis
Prior to data analysis, images showing inhomogeneous surfaces,
e.g., due to mechanical damage of the surface or impurities,
were excluded from the analysis by automated artifact detection,
which is briefly described in the following: Each original image
was converted to a binary image by replacing all pixels having
intensities above or equal the mean pixel intensity of the
regarding image plus one standard deviation with the number
one, all others with the number zero. In the next step, erosion was
applied to these binary images by using a rectangular structuring
element with a size of 31 × 31 pixels. After erosion, the binary
image was dilated using the same structuring element as for
erosion. Each cluster that consisted of connected pixels with
the intensity one in the binary image after dilatation was then
analyzed in the original image. Clusters showing either a mean
pixel intensity of above 4000, a standard deviation of pixel
intensities above 2800, or a skewness of<0 in the original images
were defined as artificial and the whole image was excluded from
the analysis. Images that had amean pixel intensity of 16,383 over
the whole image in at least one channel were included for image
analysis although they were excluded by the artifact detection,
because those images are estimated as being saturated, but not
artificial.
To account for inhomogeneous illumination, only the central
“region of interest” containing 500 × 500 pixels of each image
were used for further analysis.
The remaining images were analyzed for colocalization: For
both channels, intensity cutoffs for exclusion of background
signal were determined. As the background signal might differ
from one matrix (i.e., PBS, CSF, and plasma fraction) to
another, the cutoff values were determined for each matrix
individually, but—in order to compare sFIDA readouts achieved
by diluting oligomers in the different matrices—in a reliable
and unbiased way. The cutoff for each channel and each matrix
was determined from the unspiked control sample to be the
value, which is exceeded by only 0.01% of total image pixels.
This value represents a reasonable compromise between efficient
background removal and retention of assay sensitivity. For
cutoffs used in this study, see Table 1.
Colocalized pixels with intensity values above the cutoffs
in both channels were counted for each image. The number
of colocalized pixels was determined for each picture and the
average pixel count from all pictures from the same sample
was referred to as “sFIDA readout”. Please note that the sFIDA
readout cannot exceed 250,000, which corresponds to the total
number of pixels per analyzed image section.
Calculation of Calibration Curves
For the calibration of assay readout (number of colocalized
pixels) to molecule concentration a weighted linear regression
analysis was performed with Matlab (The MathWorks, Natick,
USA) from experimental data points within the linear detection
range (CSF: 100 pM to 10 fM; PBS: 10 pM to 10 fM; plasma
fraction: 10 pM to 10 fM) with respective weights calculated as
1/readout. In cases of readout= 0 the weight was determined as 1.
Statistics
In order to statistically assess differences between sFIDA
readouts of different concentrations of oligomers diluted in
the same matrix, two-way omnibus Kruskal-Wallis test was
used for comparison of more than two groups. Post-hoc
TABLE 1 | Cutoffs for the different body fluids.
Matrix Cutoff channel 635nm Cutoff channel 488nm
CSF 3268 2339
PBS 4082 2773
Plasma fraction 4259 2028
Cutoffs were obtained for each channel and matrix by allowing only 0.01% of all pixels to
be above background signal for negative controls.
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analysis was performed by using two-tailed Mann-Whitney-
U test and p-value adjustment according to Benjamini and
Hochberg (1995) in order to account for multiple testing. By
Mann-Whitney-U test, sFIDA readouts from each concentration
were compared to the next lower one. Additionally, sFIDA
readouts from blank samples were compared to readouts from
10 to 100 fM. The false discovery rate controlling procedure
after Benjamini and Hochberg was calculated for 0.05 (for
significant results, indicated with ∗) and 0.01 (for very significant
results, indicated with ∗∗). Kruskal-Wallis and Mann-Whitney-
U test were calculated using the statistical software Origin
(OriginLab Corporation, Northampton, USA), false discovery
rate controlling procedure after Benjamini and Hochberg was
calculated in Microsoft Excel (Microsoft Corporation, Redmond,
USA).
RESULTS
Detection of Stabilized Oligomers by sFIDA
In a first set of experiments we sought to find out if the
stabilized oligomers can be sensitively detected by the sFIDA
assay. Therefore, a log10 dilution series of oligomers in PBS
with concentrations ranging from 1 nM to 1 fM was subjected
to sFIDA analysis in quadruplicate determination. As can be seen
in Figure 2, the sFIDA readout correlated well with the applied
concentration of stabilized oligomers in the range of 100 pM
down to 1 fM. The readouts from 1 nM to 100 pM oligomers in
PBS reached saturation, which means that all pixels were above
cutoff in both channels. At the lower end of the dilution series, the
sFIDA readout of the lowest oligomer concentration (1 fM) did
not differ significantly from the readouts from 10 fM oligomers
and the blank control. However, there was a significant difference
in the sFIDA readouts from 10 fM oligomers and the blank
control.
Spiking of CSF, PBS, and EDTA Plasma
Fraction with Stabilized Oligomers
After demonstrating the ability to detect even femtomolar
concentrations of stabilized oligomers diluted in buffer, we
investigated if different body fluid environments affect the
sensitivity of oligomer detection by sFIDA. To check for matrix
effects that possibly attenuate the specific signal of Aβ oligomers,
the oligomers were spiked into CSF and blood plasma from
healthy, non-demented control subjects. All samples containing
oligomers were determined fourfold by sFIDA analysis, while
each blank sample was measured 21-fold. Figure 3 shows the
mean sFIDA readouts for all samples.
The sFIDA readout correlated well with the oligomer
concentration down to 1 fM. However, there was no significant
difference in the readouts of 10 fM as compared to 1 fM, as well
as in the readouts from the blank sample compared to 1 and 10
fM oligomers spiked into CSF. sFIDA readouts from 100 fM and
the blank sample differed significantly.
For plasma samples, there was even a very significant
difference between the sFIDA readouts of 10 fM and blank
sample.
FIGURE 2 | sFIDA readout of stabilized oligomers diluted in PBS.
Columns and error bars represent the mean values and standard deviations
calculated from a fourfold determination of samples containing oligomers. The
blank was determined 21-fold. Cutoffs for each channel were set to discard
virtually all background from control samples except for 25 pixels, which are
0.01% of all pixels. This led to the following cutoff values (channel
635 nm/channel 488 nm): 4082/2773. Please note that the number of
colocalized pixels (sFIDA readout) is lower than the number of pixels above
background in the single channels. n.s., not significant; *p ≤ 0.05; **p ≤ 0.01.
FIGURE 3 | sFIDA readout of stabilized oligomers diluted in CSF, PBS,
and a plasma fraction. Shown are mean values and standard deviations
from fourfold (samples containing stabilized oligomers) or 21-fold (all blanks)
determinations. Cutoffs for channel 635 nm/channel 488 nm: CSF, 3268/2339;
PBS, 4082/2773; plasma fraction, 4259/2028.
Lower Limits of Detection and Lower
Limits of Quantification for Stabilized
Oligomers Diluted in PBS, CSF, and the
Plasma Fraction
As the concentration of Aβ oligomers in body fluids like CSF and
blood is presumably very low (Bruggink et al., 2013; Hölttä et al.,
2013; Savage et al., 2014), the lower limit of detection (LLOD) is
an important characteristic of every assay for the determination
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of Aβ oligomer concentration. To identify the LLOD for each
matrix used in this report, each blank sample was determined
21-fold. The LLOD was calculated as the mean sFIDA readout
from all blank samples plus three times the standard deviation. By
establishing a calibration curve from the dilution series, the Aβ
oligomer concentration corresponding to the calculated sFIDA
readout was then determined. The resulting LLODs were 22 fM
for stabilized oligomers diluted in PBS, 18 fM in CSF, and 14 fM
in the plasma fraction.
The lower limits of quantification (LLOQ) were calculated as
the mean sFIDA readout from all blank samples plus ten times
the standard deviation. The same calibration curves as used for
determination of LLOD were applied, leading to the following
concentrations: 32 fM for stabilized oligomers diluted in PBS,
24 fM for dilution in CSF, and 22 fM for dilution in the plasma
fraction.
DISCUSSION
In the present work we applied stabilized Aβ oligomers as
standard in the sFIDA assay. For dilutions in PBS, CSF from
control donors, and blood plasma from control donors, the
sFIDA readout correlated with the oligomer concentration
over five to six orders of magnitude. Although oligomer
concentrations in the upper picomolar range are presumably
not physiologically relevant, the observed linearity over several
orders of magnitude is useful to check assay functionality
and to facilitate assay calibration. The calculated LLODs for
oligomers diluted in PBS, CSF, and a plasma fraction were in
the range of 14–22 fM particle concentration. We can exclude
that endogenous Aβ oligomers, which are possibly present also
in healthy subjects, contribute significantly to the assay readout,
since the intensity cutoff was determined based on the non-
spiked control samples.
For the lower concentrations from 1 pM down to 1 fM, a
linear relation between the sFIDA readout and concentrations
of Aβ oligomers was observed. We expect that to be the
relevant concentration range for analysis of biological samples,
as published concentrations of oligomers in CSF are in the
femtomolar to low picomolar range (stated as monomeric
concentrations of Aβ; oligomeric concentrations are even lower;
Bruggink et al., 2013; Hölttä et al., 2013; Savage et al., 2014).
LLODs often refer to the concentration or mass of the total
applied peptide, although the actual portion of oligomerized
Aβ and the size of Aβ oligomers in the preparations is mostly
unknown (Santos et al., 2007; Sancesario et al., 2012). The
concentration of 14 fM of the stabilized oligomers used in this
study corresponds to 3.1 pM (13.9 ng/L) monomeric Aβ1–42. The
LLOD given in mass per volume is roughly in the same range
or above the limits of detection published for some Aβ oligomer
specific ELISA (Fukumoto et al., 2010; Bruggink et al., 2013;
Hölttä et al., 2013; Savage et al., 2014). In principle, sFIDA allows
detection and quantification of single particles of oligomers
consisting of approximately 220 Aβ monomers.
Although the stabilized oligomers used in this study might
not accurately reflect the properties of native Aβ oligomers in
terms of composition, mass, and structural heterogeneity, they
are nevertheless a valuable tool for assay development, assay
calibration, and determination of inter- and intra-assay variation
due to their stability and homogenous size. While heterogeneous
Aβ oligomer standards would resemble endogenous conditions
more closely, it is hardly possible to reliably produce such
standards with minimal batch-to-batch-variations thus limiting
their use in assay validation.
The stabilized oligomers are advantageous with regard to long
term stability and they can easily be distributed to compare
inter-laboratory results. This enables to thoroughly validate and
calibrate an assay, which is a very important feature in assay
development. However, the applicability of this standard for
biological samples will have to be addressed in future studies.
Quantification of very small oligomers in body fluids might
emphasize the need for even smaller standard oligomers than the
ones used in this study.
We have previously shown that monomers of synthetic Aβ
give not rise to significant signals in the sFIDA assay by using
overlapping epitopes in the capture and detection system (Wang-
Dietrich et al., 2013). When analyzing native CSF samples in
diagnostic setups, however, experimental conditions (i.e., pH,
incubation times, freeze/thaw cycles) have to be carefully adjusted
to avoid false-positive signals due to artificial aggregation of
endogenous Aβ monomers.
In the present version of the assay, two N-terminal antibodies
were used for capturing and detection of Aβ, i.e., Nab228 (epitope
Aβ1-11) and 6E10 (epitope Aβ3-8). By using alternative capture
and probe antibodies, it is not only possible to detect oligomers
composed of different Aβ isoforms, but also to detect hybrid
aggregates composed of different peptides or proteins. Therefore,
sFIDA assay can in future be applied for scientific purpose in
order to investigate the presence and pathological relevance of
different oligomeric species in body fluids or brain homogenates
of patients with different neurodegenerative diseases, such as AD.
Additionally, after thorough investigation and validation of the
assay and the measured targets, sFIDA might either give extra
information useful for diagnostics or even measure oligomeric
biomarkers that allow a reliable diagnosis, and might be useful
for disease monitoring in clinical trials during treatment.
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